HSPA1A and prostate cancer: In conclusions, we have identified a new AR/AR-V7 degrader named ARVib and showed that ARVib effectively degrades AR/AR-V7 protein through the ubiquitin-proteasome pathway mediated by the HSP70/STUB1 complex and attenuates AR/AR-V7 downstream target gene expression in prostate cancer cells.